Table 1 The mRNA microarray gene expression and RNA-Seq data used in this study. The dataset title is used hereafter as a dataset identifier
Dataset | Cancer type | Time after treatment (h) | Number of samples | |
|---|---|---|---|---|
Control | After treatment | |||
I. Platinum-based agents | ||||
 E-GEOD-38122 [103] | Hepatocyte carcinoma | 24 | 3 | 3 |
 GSE47980 [104] | Melanoma | 24 | 9 | 9 |
 GSE38545 | Ovarian cancer | 24 | 3 | 3 |
 GSE13525 [105] | Ovarian cancer | 24 | 2 | 2 |
 E-GEOD-8057 [106] | Ovarian cancer | 24 | 4 | 4 |
 GSE51952 [107] | Hepatocyte carcinoma | 24 | 3 | 3 |
 GSE66493 | Glioblastoma | 24 | 3 | 3 |
 GDS3910 [108] | Breast cancer | 11 | 2 | 2 |
 E-MTAB-3645 [109] | Ovarian cancer | 72 | 3 | 3 |
II. Paclitaxel | ||||
 E-GEOD-50831 [110] | Ovarian cancer | 24 | 63 | 63 |
 E-GEOD-50830 [110] | Endometrial adenocarcinoma | 24 | 55 | 57 |
 E-GEOD-50811 [110] | Breast cancer | 24 | 79 | 81 |
III. Irradiation (two meta-analyses for cancer and embryonic cells) | ||||
 E-GEOD-59732 [111] | Breast cancer | 24 | 48 | 48 |
 E-GEOD-59861 [112] | Skin fibroblasts | 0, 3, 6, 12, 24 | 4 | 12 |
IV. Hypoxia | ||||
 E-GEOD-18494 [113] | Hepatocyte carcinoma, glioblastoma, breast cancer | 12 | 9 | 9 |
 E-GEOD-53012 [114] | Prostate cancer, ovarian cancer, melanoma | 72 | 9 | 9 |
 E-MTAB-3645 [109] | Ovarian cancer | 72 | 3 | 3 |
 E-GEOD-17188 [115] | Breast cancer | 24 | 4 | 4 |
V. Tyrosine kinase inhibitors | ||||
 E-TABM-585 [116] | Lung cancer | 20 | 21 | 27 |
VI. Topoisomerase inhibitors | ||||
 E-GEOD-47013 [117] | Multiple myeloma | – | 3 | 3 |
 E-GEOD-13477 [118] | Breast cancer | 24 | 2 | 2 |
 E-GEOD-19638 [119] | Breast cancer | – | 2 | 2 |
 E-GEOD-39870 [120] | Breast cancer | – | 3 | 3 |
Splicing analysis | ||||
 GSE69405 [37] | Lung adenocarcinoma | 48 | 12 | 12 |
 GSE89127 [34] | Gastric carcinoma, lung adenocarcinoma, melanoma, urinary bladder carcinoma | 48 | 18 | 18 |
Spliceostatin | ||||
 GSE72156 [58] | Cervical cancer | – | 3 | 3 |
Pladienolide | ||||
 E-GEOD-67770 [57] | Ovarian cancer | – | 2 | 2 |